LY3200882 + cisplatin

LY3200882 + cisplatin is a **combination therapy** comprised of LY3200882—a next-generation, selective small molecule inhibitor of transforming growth factor beta receptor type 1 (TGFβR1)—and cisplatin, a platinum-based chemotherapy commonly used in various cancers. LY3200882 functions by inhibiting the TGFβ pathway, which is deregulated in many cancers and contributes to tumor growth, immune evasion, epithelial-mesenchymal transition, and angiogenesis. Cisplatin acts primarily by inducing DNA crosslinking, leading to apoptosis of rapidly dividing tumor cells. The combination has been investigated for the treatment of head and neck squamous cell cancer (HNSCC), with LY3200882 administered orally in combination with cisplatin and radiation in clinical trials[1][5].